All In Biotech

Drug Trial Radar · NCT07684612

A Study to Investigate Mocertatug Rezetecan With Bevacizumab Compared With Platinum Doublet With Bevacizumab in Participants With Platinum-sensitive Ovarian Cancer (BEHOLD-Ovarian02)

A Randomized, Open-Label, Multicenter, Phase 3 Study to Investigate Mocertatug Rezetecan With Bevacizumab Compared With Platinum Doublet With Bevacizumab in Participants With Platinum-Sensitive Ovarian Cancer

Last checked: Nov 20, 2026Latest source record: Oct 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 690 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

690

Planned (sponsor's estimate)

Start

Sep 8, 2026

Primary completion

May 21, 2030

Study completion Apr 22, 2033

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
Collaborators
GOG, ENGOT, APGOT
First posted
Jul 6, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study specifically aims to evaluate how well mocertatug rezetecan (Mo-Rez) in combination with bevacizumab works in treating platinum-sensitive ovarian cancer compared to standard treatments by checking whether it makes cancers smaller or disappear completely and if it helps participants live longer. The study also assesses whether Mo-Rez in combination with bevacizumab is safe and tolerated well by participants compared to standard treatments and aims to provide a better understanding of the main side effects of Mo-Rez.

Conditions

  • Ovarian Neoplasms

Interventions

  • Mocertatug rezetecan (Mo-Rez)Drug

    Mocertatug rezetecan will be administered

  • CarboplatinDrug

    Carboplatin will be administered

  • PaclitaxelDrug

    Paclitaxel will be administered

  • GemcitabineDrug

    Gemcitabine will be administered

  • Pegylated liposomal doxorubicin (PLD)Drug

    PLD will be administered

  • BevacizumabDrug

    Bevacizumab will be administered

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression Free Survival (PFS) by BICRTime frame: Up to approximately 191 weeks

Locations

9 sites in 4 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Newcastle, New South Wales, Australia · Recruiting

  • GSK Investigational Site

    Toronto, Ontario, Canada · Recruiting

  • GSK Investigational Site

    Montreal, Quebec, Canada · Recruiting

  • GSK Investigational Site

    Hokkaido, Japan · Recruiting

  • GSK Investigational Site

    Hyōgo, Japan · Recruiting

  • GSK Investigational Site

    Ibaraki, Japan · Recruiting

  • GSK Investigational Site

    Seoul, South Korea · Recruiting

  • GSK Investigational Site

    Seoul, South Korea · Recruiting

  • GSK Investigational Site

    Seoul, South Korea · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.